SION
What one share of Sionna Therapeutics holds
Pharmaceutical Preparations
We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to people with CF.
Sionna Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$2.17 |
|---|---|
| Capex (buildings and equipment) | $0.01 |
| Free cash flow | −$1.70 |
| Cash and investments | $1.40 |
| Book value | $5.88 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2024 | — | −$15.99 | $0.01 | −$13.69 | — | −$34.66 |
| 2025 | — | −$1.88 | $0.01 | −$1.67 | — | $6.86 |